12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tresiba insulin degludec regulatory update

Novo Nordisk said the First Committee on Drugs of Japan's Pharmaceutical Affairs issued a positive recommendation on a marketing application for insulin degludec to treat Type I and Type II diabetes. Novo expects Japan's Ministry of Health, Labor...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >